XML 49 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies - Additional Information (Detail)
9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
Segment
Customer
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2012
USD ($)
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
Maturities period 24 months      
Unrealized gain on held-to-maturity securities $ 900,000      
Number of operating segments | Segment 1      
ASU No. 2018-18        
Significant Accounting Policies [Line Items]        
Change in accounting principle, accounting standards update, adopted [true false] true      
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020      
Change in accounting principle, accounting standards update, immaterial effect [true false] true      
ASU No. 2018-13        
Significant Accounting Policies [Line Items]        
Change in accounting principle, accounting standards update, adopted [true false] true      
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020      
Change in accounting principle, accounting standards update, immaterial effect [true false] true      
ASU No. 2016-13        
Significant Accounting Policies [Line Items]        
Change in accounting principle, accounting standards update, adopted [true false] true      
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020      
Change in accounting principle, accounting standards update, immaterial effect [true false] true      
Minimum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
Maximum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 60 days      
Embedded Derivative Financial Instruments | BioPharma Debt        
Significant Accounting Policies [Line Items]        
Maximum repayment of future revenue and receivables       $ 150,000,000.0
Fair value of embedded derivative liability $ 0   $ 0  
Gain (loss) on change in fair value of derivative liabilities $ 0 $ 0    
Embedded Derivative Financial Instruments | BioPharma Debt | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 6.00%   6.00%  
Derivative liability fair value assumptions, market yields 5.40%   5.20%  
Embedded Derivative Financial Instruments | BioPharma Debt | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 11.50%   11.50%  
Derivative liability fair value assumptions, market yields 16.40%   16.80%  
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 1 year 2 months 12 days   1 year 10 months 24 days  
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 6 years 6 months   7 years 3 months 18 days  
Short Term Investments        
Significant Accounting Policies [Line Items]        
Maturities period 12 months      
Long Term Investments        
Significant Accounting Policies [Line Items]        
Maturities period 12 months      
Money Market Instruments        
Significant Accounting Policies [Line Items]        
Maturities period 90 days      
Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Number of customers | Customer 3      
Customer A | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 25.00% 25.00%    
Customer A | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 37.00% 42.00%    
Customer B | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 37.00% 36.00%    
Customer B | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 32.00% 23.00%    
Customer C | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 30.00% 29.00%    
Customer C | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 25.00% 28.00%